News

Guggenheim’s Seamus Fernandez cut his rating on Novo Nordisk stock to Hold from Buy on Thursday, as did Evan David Seigerman ...
The mid-stage trial results announced by the pharmaceutical giant showed that patients taking orforglipron lost an average of ...
Shares of Novo Nordisk, the Danish pharmaceutical company behind weight-loss drugs Ozempic and Wegovy, plummeted this week.
Novo Nordisk , the producer of Ozempic, Wegovy and other medications, will invest 6.4 billion reais ($1.09 billion) in Brazil ...
Patients on the new pill also lost weight — up to 16 pounds without reaching a plateau at the study’s end. Side effects were ...
Eli Lilly shares are now positive for the year, up 10% since the start of January.
Pharmaceutical company Eli Lilly’s study of its tablet, orforglipron, has raised hopes of an effective and easy-to-use ...
Novo Nordisk's stocks face YTD struggles due to trial results and tariffs, but strong fundamentals and outlook justify a Buy.